CG Oncology, Inc. (CGON) reported positive results from its phase 3 BOND-003 study, which used its monotherapy immunotherapy drug known as cretostimogene for the treatment of patients with high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results